Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Apr 20;37(12):946-953.
doi: 10.1200/JCO.18.02018. Epub 2019 Feb 27.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Branimir I Sikic  1 , Nehal Lakhani  2 , Amita Patnaik  3 , Sumit A Shah  1 , Sreenivasa R Chandana  2 , Drew Rasco  3 , A Dimitrios Colevas  1 , Timothy O'Rourke  2 , Sujata Narayanan  1 , Kyriakos Papadopoulos  3 , George A Fisher  1 , Victor Villalobos  4 , Susan S Prohaska  1 , Maureen Howard  1 , Muralidhar Beeram  3 , Mark P Chao  5 , Balaji Agoram  5 , James Y Chen  5 , Jie Huang  5 , Matthew Axt  5 , Jie Liu  5 , Jens-Peter Volkmer  5 , Ravindra Majeti  1   5 , Irving L Weissman  1 , Chris H Takimoto  5 , Dana Supan  1 , Heather A Wakelee  1 , Rhonda Aoki  1 , Mark D Pegram  1 , Sukhmani K Padda  1
Affiliations
Clinical Trial

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Branimir I Sikic et al. J Clin Oncol. .

Abstract

Purpose: To evaluate the safety, pharmacokinetics, and pharmacodynamics of Hu5F9-G4 (5F9), a humanized IgG4 antibody that targets CD47 to enable phagocytosis.

Patients and methods: Adult patients with solid tumors were treated in four cohorts: part A, to determine a priming dose; part B, to determine a weekly maintenance dose; part C, to study a loading dose in week 2; and a tumor biopsy cohort.

Results: Sixty-two patients were treated: 11 in part A, 14 in B, 22 in C, and 15 in the biopsy cohort. Part A used doses that ranged from 0.1 to 3 mg/kg. On the basis of tolerability and receptor occupancy studies that showed 100% CD47 saturation on RBCs, 1 mg/kg was selected as the priming dose. In subsequent groups, patients were treated with maintenance doses that ranged from 3 to 45 mg/kg, and most toxicities were mild to moderate. These included transient anemia (57% of patients), hemagglutination on peripheral blood smear (36%), fatigue (64%), headaches (50%), fever (45%), chills (45%), hyperbilirubinemia (34%), lymphopenia (34%), infusion-related reactions (34%), and arthralgias (18%). No maximum tolerated dose was reached with maintenance doses up to 45 mg/kg. At doses of 10 mg/kg or more, the CD47 antigen sink was saturated by 5F9, and a 5F9 half-life of approximately 13 days was observed. Strong antibody staining of tumor tissue was observed in a patient at 30 mg/kg. Two patients with ovarian/fallopian tube cancers had partial remissions for 5.2 and 9.2 months.

Conclusion: 5F9 is well tolerated using a priming dose at 1 mg/kg on day 1 followed by maintenance doses of up to 45 mg/kg weekly.

Trial registration: ClinicalTrials.gov NCT02216409.

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
Hu5F9-G4 (5F9) pharmacokinetics and effects on hemoglobin and reticulocyte levels. (A) Concentration of 5F9 (mean ± standard deviation) versus time during week 5 over the evaluated weekly dose range (1 to 45 mg/kg; number of patients per dose range, three to 30). (B) Anemia with compensatory reticulocytosis in one patient.
FIG 2.
FIG 2.
Pharmacodynamics of Hu5F9-G4. (A) RBC receptor occupancy. (B) WBC receptor occupancy. (C) IgG4 immunohistochemical staining in a lymph node with tumor involvement obtained from a 70-year-old patient with ovarian cancer treated with 30 mg/kg of 5F9. She remained on study for 7 months with a best overall response of stable disease. 1/3 is 1 mg/kg priming dose and 3 mg/kg weekly dosing. 1/10 is 1 mg/kg priming dose and 10 mg/kg weekly dosing. 1/20 is 1 mg/kg priming dose and 20 mg/kg weekly dosing. Po, post-infusion sample collection; Pr, pre-infusion sample collection.
FIG 3.
FIG 3.
Hu5F9-G4 partial responses observed in (A) a patient with clear cell ovarian cancer and (B) a patient with fallopian tube cancer.
See this image and copyright information in PMC

Comment in

References

    1. Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001;11:130–135. - PubMed
    1. Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142:699–713. - PMC - PubMed
    1. Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109:6662–6667. - PMC - PubMed
    1. Chao MP, McKenna KM, Cha A, et al: The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies. Cancer Immunol Res 4, 2016 (abstr PR13)
    1. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286–299. - PMC - PubMed

Publication types

MeSH terms

Associated data